The Motley FoolT3·40mo ago
GNOM Global X Genomics & Biotechnology ETF
ETF 66.46 DelayedETF quote, holdings, sector allocation, technicals, and options analytics. Expected move IV rank history Fibonacci levels
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
GNOM
$66.46
—
Key stats
$66.46
- 52-Week Range
- $41.16 – $74.19
- YTD
- +45.54%
- IV Rank (30D)
- 0.0
- Straddle Price
- $5.00
- P/C Vol Ratio
- 0.57
- Open
- $65.39
- Day Range
- $65.39 – $66.75
- Volume
- 16,261
- Prev Close
- $65.58
About
Global X Genomics & Biotechnology ETF (GNOM) ETF
No description available.
- Exchange
- XNAS
- Inception
- 2019-04-05
- Has Options
- Yes
Fund profile
holdings as of Oct 23, 2026issuer datathrough May 2026flows, SEC filings
- Expense ratio
- 0.50% prospectus, filed Mar 27, 2026
- Assets
- $105M shares × price, Oct 23, 2026
- Trailing yield
- 0.99% paid semi-annual
- Average daily volume
- $2.5M 30 sessions
- Holdings
- 52 top 10 are 54.3%
- Listed
- Apr 5, 2019 Nasdaq
- Tracking difference
- -0.39 pts vs index, after fees, FY 2025
Cost58
Liquidity46
Scale38
Diversification52
Moves with. Small caps over large (12% of its variance, beta 0.91); US large-cap stocks (9% of its variance, beta 0.51); Long Treasuries (6% of its variance, beta 0.70); Gold (4% of its variance, beta 0.14). These factors explain 37% of its daily moves over the last year.
Stated objective. "The Global X Genomics & Biotechnology ETF (""Fund"") seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index (""Underlying Index"")." (from the fund's prospectus)
All 52 holdingsFlow historySimilar fundsOverlap toolAll Biotech & Health Innovation ETFs
Fund flows
through May 2026SEC filings- May 2026
- +$1.3M latest reported month
- Latest 3 months
- +$1.4M +2.4% of assets
- Latest 12 months
- −$8.1M −14.6% of assets
View as a table
| Month | Net flow |
|---|---|
| May 2026 | +$1.3M |
| Apr 2026 | $0 |
| Mar 2026 | +$52K |
| Feb 2026 | −$1.9M |
| Jan 2026 | −$1.9M |
| Dec 2025 | $0 |
| Nov 2025 | −$1.2M |
| Oct 2025 | $0 |
| Sep 2025 | −$2.1M |
| Aug 2025 | +$84K |
| Jul 2025 | −$2.4M |
| Jun 2025 | $0 |
Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 81 months ago
Similar funds
| Fund | Overlap | Fee | Assets | 1Y | |
|---|---|---|---|---|---|
| GNMXCorgi Genomics & Precision Medicine ETF | 47% | 0.35% | $1.3M | — | compare |
| ARKGARK Genomic Revolution ETF | 42% | 0.75% | $1.9B | +57.5% | compare |
| WDNAWisdomTree BioRevolution Fund | 34% | 0.45% | $4.6M | +34.3% | compare |
| HELXFranklin Genomic Advancements ETF | 30% | 0.50% | $34M | +28.8% | compare |
| PBEInvesco Biotechnology & Genome ETF | 30% | 0.58% | $428M | +35.6% | compare |
Ranked by how much of the two portfolios is the same securities.
Look-through: what the holdings say
weights as of Oct 23, 2026issuer data- Holdings vs fair value
- +2.2% 22% under, 46% over · 95% covered
- Price / earnings
- — 65% loss-making · 87% covered
- Price / book · sales
- 5.4 · 8.3 revenue growth +9.6%
- Above 200-day average
- 75% 58% above 50-day · by weight
- Short interest
- 10.9% of float, weighted · 4.4 days to cover
- Insider buying
- 0% of weight had net insider buying, 90 days; 63% net selling
- 13F holders
- −0.1% change in shares held by institutions, latest quarter
- Reporting earnings
- 21.9% of weight in 7 days; 82.6% in 14
Holdings reporting in the next 14 days · weighted implied move this week 2.62%
Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.
What changed in the portfolio
Feb 28, 2026 → May 31, 2026| Action | Holding | Weight before | Weight after | Shares vs flows |
|---|---|---|---|---|
| Decrease | MRNAMODERNA, INC. | 7.86% | 3.28% | −53.3% |
| Exit | RNAMAvidity Biosciences Inc | 3.75% | — | — |
| Exit | ALNYALNYLAM PHARMACEUTICALS, INC. | 2.51% | — | — |
| Decrease | PRAXPraxis Precision Medicines Inc | 6.23% | 4.01% | −39.0% |
| New position | CAICARIS LIFE SCIENCES, INC. | — | 2.03% | — |
| New position | BillionToOne Inc | — | 1.97% | — |
| Increase | LEGNLegend Biotech Corp | 2.14% | 4.05% | +30.2% |
| Increase | TWSTTwist Bioscience Corp | 2.30% | 3.97% | +19.5% |
| Decrease | ARWRARROWHEAD PHARMACEUTICALS, INC. | 5.69% | 4.07% | −42.7% |
| Decrease | BMYBRISTOL-MYERS SQUIBB COMPANY | 2.65% | 1.16% | −53.2% |
0 new, 0 exited, 0 increased and 0 decreased between the fund's two latest holdings reports; turnover 1.0%. Full holdings and history
Under the hood
fiscal year to Nov 30, 2025SEC census- Authorized participants
- 6 active of 22 with agreements; top 3 did 86%
- Created · redeemed
- $84K · $23M over the fiscal year
- Redemptions in kind
- 100% creations 0% in kind
- Creation unit
- 10,000 shares
- Securities lending
- 7.46% of assets on loan on average; earned 16.3 bp
- Return vs index
- -0.39 pts after fees; +0.15 before; daily s.d. 1.21
- Diversification status
- Non-diversified may concentrate in fewer issuers
From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.
ETF Profile
holdings as of 2026-10-26
Holdings
52
AUM
$106.1M
Provider
Global X
Inception
2019-04-05
Exchange
XNAS
Data As Of
2026-10-26
Expense Ratio
0.50%
Dividend Yield
0.98%
Distribution
Semi-Annual
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-06-29 | 2026-07-07 | $0.0579 | CD |
| 2025-12-30 | 2026-01-07 | $0.5912 | CD |
| 2025-06-27 | 2025-07-07 | $0.0083 | CD |
| 2021-12-30 | 2022-01-07 | $0.0065 | CD |
Asset Allocation
Top Holdings
top 50 of 52 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| MRNA | MODERNA INC | 10.30% | Equity (US) | US |
| TWST | TWIST BIOSCIENCE CORP | 6.42% | Equity (US) | US |
| TXG | 10X GENOMICS INC-CLASS A | 6.21% | Equity (US) | US |
| ILMN | ILLUMINA INC | 5.98% | Equity (US) | US |
| NTRA | NATERA INC | 5.61% | Equity (US) | US |
| GH | GUARDANT HEALTH INC | 5.57% | Equity (US) | US |
| QGEN | QIAGEN N.V. | 3.63% | Equity (US) | — |
| TECH | BIO-TECHNE CORP | 3.58% | Equity (US) | US |
| — | GENSCRIPT BIOTECH CORP | 3.45% | Equity (Foreign) | — |
| VRTX | VERTEX PHARMACEUTICALS INC | 3.40% | Equity (US) | US |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 2.97% | Equity (US) | US |
| CAI | CARIS LIFE SCIENCES INC | 2.94% | Equity (US) | US |
| VCYT | VERACYTE INC | 2.82% | Equity (US) | US |
| CRSP | CRISPR THERAPEUTICS AG | 2.50% | Equity (US) | — |
| CDNA | CAREDX INC | 2.38% | Equity (US) | US |
| BNTX | BIONTECH SE-ADR | 2.30% | Equity (Foreign) | DE |
| ARWR | ARROWHEAD PHARMACEUTICALS IN | 2.30% | Equity (US) | US |
| PRAX | PRAXIS PRECISION MEDICINES I | 2.28% | Equity (US) | US |
| LEGN | LEGEND BIOTECH CORP-ADR | 2.27% | Equity (US) | — |
| LLY | ELI LILLY & CO | 1.99% | Equity (US) | US |
| GILD | GILEAD SCIENCES INC | 1.72% | Equity (US) | US |
| BEAM | BEAM THERAPEUTICS INC | 1.66% | Equity (US) | US |
| BLLN | BILLIONTOONE INC CL A | 1.66% | Equity (US) | US |
| SRPT | SAREPTA THERAPEUTICS INC | 1.35% | Equity (US) | US |
| — | ASTRAZENECA PLC | 1.26% | Equity (Foreign) | GB |
| WGS | GENEDX HOLDINGS CORP | 1.19% | Equity (US) | US |
| RARE | ULTRAGENYX PHARMACEUTICAL IN | 1.13% | Equity (US) | US |
| DHR | DANAHER CORP | 1.11% | Equity (US) | US |
| VIR | VIR BIOTECHNOLOGY INC | 0.96% | Equity (US) | US |
| NTLA | INTELLIA THERAPEUTICS INC | 0.95% | Equity (US) | US |
| BMY | BRISTOL-MYERS SQUIBB CO | 0.93% | Equity (US) | US |
| QURE | UNIQURE NV | 0.90% | Equity (US) | — |
| STOK | STOKE THERAPEUTICS INC | 0.89% | Equity (US) | US |
| PSNL | PERSONALIS INC | 0.82% | Equity (US) | US |
| MRVI | MARAVAI LIFESCIENCES HLDGS-A | 0.60% | Equity (US) | US |
| PACB | PACIFIC BIOSCIENCES OF CALIF | 0.46% | Equity (US) | US |
| MYGN | MYRIAD GENETICS INC | 0.40% | Equity (US) | US |
| WVE | WAVE LIFE SCIENCES INC | 0.37% | Equity (US) | US |
| A | AGILENT TECHNOLOGIES INC | 0.37% | Equity (US) | US |
| BRKR | BRUKER CORP | 0.32% | Equity (US) | US |
| FLGT | FULGENT GENETICS INC | 0.30% | Equity (US) | US |
| MLAB | MESA LABORATORIES INC | 0.28% | Equity (US) | US |
| PRME | PRIME MEDICINE INC | 0.26% | Equity (US) | US |
| DGX | QUEST DIAGNOSTICS INC | 0.26% | Equity (US) | US |
| RGNX | REGENXBIO INC | 0.23% | Equity (US) | US |
| BNTC | BENITEC BIOPHARMA INC | 0.21% | Equity (US) | US |
| RCKT | ROCKET PHARMACEUTICALS INC | 0.18% | Equity (US) | US |
| EDIT | EDITAS MEDICINE INC | 0.18% | Equity (US) | US |
| LAB | STANDARD BIOTOOLS INC | 0.14% | Equity (US) | US |
| CRBU | CARIBOU BIOSCIENCES INC | 0.04% | Equity (US) | US |
Geographic Breakdown
Non-Equity Breakdown
Global X Genomics & Biotechnology ETF ·
NPORT-P period 2026-05-31
(filed 2026-07-29)
Net assets:
$56M
· 51 total positions
· equity 99.90%
· non-equity 3.05%
Non-equity holdings
— 1 positions,
3.05% of NAV
| Category | Weight | Value | Positions |
|---|---|---|---|
| Repurchase agreement | 3.05% | $1.7M | 1 |
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 4.52% | -19.22% | 8.47% | -7.96% | 3.82% | 4.43% | -0.99% |
| Feb | -6.28% | -6.47% | -8.48% | 9.41% | -7.50% | -0.55% | -3.31% |
| Mar | -9.86% | -1.70% | -3.30% | -7.40% | -10.47% | -7.17% | -6.65% |
| Apr | -0.62% | -18.07% | -0.20% | -13.29% | 5.41% | 2.60% | -4.03% |
| May | -2.18% | -8.61% | -1.29% | 0.40% | -3.75% | 9.39% | -1.01% |
| Jun | 15.98% | 4.44% | -2.26% | 1.46% | 6.44% | 17.11% | 7.20% |
| Jul | -8.86% | 12.93% | 1.40% | 11.72% | 2.26% | -5.94% | 2.25% |
| Aug | 5.60% | -0.93% | -6.88% | -0.09% | 6.42% | 17.36% | 3.58% |
| Sep | -9.85% | -10.42% | -10.71% | 1.63% | 4.92% | 8.83% | -2.60% |
| Oct | -2.90% | 4.53% | -10.70% | -6.65% | 13.93% | -3.37%* | -0.86% |
| Nov | -6.06% | 1.73% | 15.22% | 3.34% | 5.69% | -- | 3.98% |
| Dec | -0.15% | -6.37% | 8.02% | -11.57% | 0.48% | -- | -1.92% |
| Total | -21.33% | -42.05% | -13.39% | -20.29% | 28.27% | 47.10% | -3.61% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $67.49
SMA 50: $66.24
SMA 200: $53.29
Current: $66.46
EMA 12: $66.68
EMA 26: $66.67
MACD: 0.0184 | Signal: -0.2792
BULLISH
ADX (14): 19.86
RANGE
+DI: 27.27
−DI: 22.15
Momentum Oscillators
RSI (14): 49.56
NEUTRAL
Stoch %K: 27.11
Stoch %D: 28.96
Williams %R: -52.25
Volume & Volatility
BB Upper: $71.53
BB Lower: $63.45
NEUTRAL
OBV: -193,907
Vol SMA 20: 36,893
Vol ROC: -70.66%
ATR: $2.20
True Range: $1.36
HV 20: 45.5%
HV 30: 42.8%
HV 60: 44.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
Here is my response:
LLM Stock Analysis Report
SYMBOL: GNOM
Executive Summary
- Overall Assessment: NEUTRAL (Confidence Level: 6/10)
- Key Drivers: Recent price action driven by technical momentum, with neutral news sentiment
- Primary Risks: Overbought RSI and MACD signals, potential for mean reversion or consolidation
- 2-3 Sentence Investment Thesis: GNOM is a neutral stock with medium-term upside potential, but faces risks from overbought conditions and market volatility.
- Recent News Sentiment Impact: No significant news headlines have impacted the stock's price recently.
Technical Analysis
- Trend Direction: Short-term: UPTREND (1-4 weeks), Medium-term: UPTREND (1-3 months)
- Support/Resistance Levels: Key price levels from moving averages and technical patterns:
- Lower support: $55.37 (SMA 50) / $48.34 (SMA 200)
- Upper resistance: $63.19 (Bollinger Bands upper band)
- Momentum Signals:
- RSI interpretation: Overbought (>70), potential sell signal
- MACD signal: Bullish momentum, with a bullish crossover above the signal line
- Bollinger Bands position: Overbought, indicating mean reversion or consolidation risk
- Volume Analysis: Volume trends and institutional interest signals:
- Volume SMA 20: $17609.48 (indicating medium-term uptrend)
- On-Balance Volume (OBV): 166104.09 (indicating accumulation)
News & Sentiment Analysis
- Recent Headlines Summary: Neutral news headlines from various sources, with no significant market-moving events
- Sentiment Assessment: Aggregate news sentiment: NEUTRAL
- Catalyst Identification: No imminent catalysts or events that could impact the stock's price
- Market Narrative: Technical momentum driving the stock's price, with neutral news sentiment not providing a clear direction
Risk & Volatility Assessment
- Beta Interpretation: Beta 1.16 (above average volatility), indicating amplification of market moves
- Volatility Regime: Current vs historical volatility levels:
- Stock Volatility: 0.31 (above average)
- Historical Volatility: HV20 51.4% / HV30 46.1% / HV60 38.6%
- Options Market Signals: IV Rank: 44.8%, indicating medium-level volatility
- Downside Protection: Support levels and risk management considerations:
- Lower support: $55.37 (SMA 50) / $48.34 (SMA 200)
Market Context & Positioning
- Sector Performance: Relative strength vs sector/market (neutral)
- Institutional Activity: Volume patterns suggesting institutional interest in accumulation
- Correlation Analysis: How stock moves relative to market (R-squared interpretation): 0.48 (above average correlation)
- Relative Valuation: Position within trading range: Neutral
Key Levels & Action Items
- Critical Price Levels: Support/resistance levels to monitor:
- Lower support: $55.37 (SMA 50) / $48.34 (SMA 200)
- Upper resistance: $63.19 (Bollinger Bands upper band)
- Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- Mean reversion or consolidation risk from overbought conditions
- Time-Sensitive Catalysts: No imminent catalysts or events that could impact the stock's price
- Risk Management: Stop-loss levels and position sizing considerations:
- Consider stop-loss around $63.19 (Bollinger Bands upper band) to limit potential losses
Please note that this analysis is based on the provided data, and actual market conditions may differ.
Generated
News
All GNOM news →
Zacks Investment ResearchT3·45mo ago
Zacks Investment ResearchT3·52mo ago
Zacks Investment ResearchT3·58mo ago
Seeking AlphaT3·60mo ago
Zacks Investment ResearchT3·62mo ago
Investing.comT3·62mo ago
Zacks Investment ResearchT3·63mo ago
Zacks Investment ResearchT3·64mo ago
Zacks Investment ResearchT3·64mo ago
Showing 1–10 of 14
Page 1 of 2
GNOM Options Activity & IV Rank
GNOM IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 33.8%
7-DTE IV: —
Expected Move: $5.00
7-DTE Move: $5.00
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 14
Put Volume: 8
P/C Volume: 0.571
BULLISH
Call OI: 7
Put OI: 9
P/C OI: 1.286
Total OI: 16
ATM Options Pricing
ATM Call: $2.50
ATM Put: $2.50
Call %: 3.8%
Put %: 3.8%
Chain Summary
Chain Volume: 69
Chain OI: 530
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 35.8% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)0.0LowOct 26
Straddle Price (30 DTE)$5.00Oct 26
Beta Analysis
Risk Metrics
Beta: 1.2412
Alpha: 31.30%
Correlation: 0.4754
R-Squared: 22.6%
Stock Volatility: 33.3%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
GNOM Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
1 filers$11.37K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Belvedere Trading LLC | $11.37K | 100.00% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
89.98K
SI % of Float
5.61%
Days to Cover
2.74
Short Vol Ratio
56.2%
Free Float
—
Float %
—
Short interest 2026-09-30 • Short volume 2026-10-26
GNOM Constituent Performance
Click any bar to view the full quote for that stock.
GNOM Constituents (48 of 48)
| Symbol | Name | Weight % | Price | 1 Day | 1 Week | 1 Month |
|---|---|---|---|---|---|---|
| MRNA | MODERNA INC | 10.30% | $198.85 | -0.62% | -12.36% | +0.80% |
| TWST | TWIST BIOSCIENCE CORP | 6.42% | $145.25 | +3.81% | +3.92% | -19.13% |
| TXG | 10X GENOMICS INC-CLASS A | 6.21% | $72.96 | +1.97% | +4.39% | -17.56% |
| ILMN | ILLUMINA INC | 5.98% | $271.04 | +0.60% | +3.19% | -0.32% |
| NTRA | NATERA INC | 5.61% | $404.9 | +0.24% | +1.37% | -1.67% |
| GH | GUARDANT HEALTH INC | 5.57% | $173.25 | +2.47% | +9.74% | -2.30% |
| QGEN | QIAGEN N.V. | 3.63% | $50.37 | -0.04% | +8.21% | +11.91% |
| TECH | BIO-TECHNE CORP | 3.58% | $72.69 | +0.19% | +0.28% | +0.25% |
| VRTX | VERTEX PHARMACEUTICALS INC | 3.40% | $517.49 | -1.23% | +3.10% | -1.93% |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 2.97% | $55.75 | -0.36% | +1.98% | -6.24% |
| CAI | CARIS LIFE SCIENCES INC | 2.94% | $32.45 | +1.42% | +5.68% | +2.22% |
| VCYT | VERACYTE INC | 2.82% | $48.2 | +0.56% | +10.05% | +6.57% |
| CRSP | CRISPR THERAPEUTICS AG | 2.50% | $49.01 | -0.77% | -2.06% | -9.39% |
| CDNA | CAREDX INC | 2.38% | $69.1 | -0.16% | +3.01% | +6.97% |
| ARWR | ARROWHEAD PHARMACEUTICALS IN | 2.30% | $58.98 | +1.65% | +3.06% | -9.90% |
| BNTX | BIONTECH SE-ADR | 2.30% | $86.86 | -1.42% | -2.63% | -12.33% |
| PRAX | PRAXIS PRECISION MEDICINES I | 2.28% | $267.39 | +5.70% | +2.78% | -6.39% |
| LEGN | LEGEND BIOTECH CORP-ADR | 2.27% | $20.39 | +5.81% | +9.33% | +9.51% |
| LLY | ELI LILLY & CO | 1.99% | $1279.14 | +0.45% | +3.13% | +7.96% |
| GILD | GILEAD SCIENCES INC | 1.72% | $158.69 | +1.70% | +3.67% | +4.26% |
| BLLN | BILLIONTOONE INC CL A | 1.66% | $111.47 | +3.43% | +10.33% | -8.43% |
| BEAM | BEAM THERAPEUTICS INC | 1.66% | $23.79 | -1.08% | -1.65% | -1.82% |
| SRPT | SAREPTA THERAPEUTICS INC | 1.35% | $17.98 | +1.41% | +1.41% | -4.36% |
| WGS | GENEDX HOLDINGS CORP | 1.19% | $61.26 | +9.10% | -7.59% | -28.71% |
| RARE | ULTRAGENYX PHARMACEUTICAL IN | 1.13% | $16.08 | +2.75% | +6.70% | +11.59% |
| DHR | DANAHER CORP | 1.11% | $232.97 | +1.07% | +3.81% | +2.48% |
| VIR | VIR BIOTECHNOLOGY INC | 0.96% | $11.04 | +4.45% | +8.13% | +5.04% |
| NTLA | INTELLIA THERAPEUTICS INC | 0.95% | $11.26 | +0.45% | -2.76% | -1.40% |
| BMY | BRISTOL-MYERS SQUIBB CO | 0.93% | $61.61 | +0.21% | +4.73% | -3.55% |
| QURE | UNIQURE NV | 0.90% | $21.65 | -3.48% | -2.48% | -44.64% |
| STOK | STOKE THERAPEUTICS INC | 0.89% | $25.46 | +1.68% | +2.58% | -0.16% |
| PSNL | PERSONALIS INC | 0.82% | $15.88 | +0.19% | +0.00% | -2.70% |
| MRVI | MARAVAI LIFESCIENCES HLDGS-A | 0.60% | $7.58 | +3.55% | +8.44% | -0.66% |
| PACB | PACIFIC BIOSCIENCES OF CALIF | 0.46% | $2.25 | +6.64% | +22.28% | +31.58% |
| MYGN | MYRIAD GENETICS INC | 0.40% | $6.02 | +3.44% | +42.99% | +41.98% |
| A | AGILENT TECHNOLOGIES INC | 0.37% | $175.96 | +1.67% | +3.57% | +0.43% |
| WVE | WAVE LIFE SCIENCES INC | 0.37% | $3.21 | +0.94% | +1.26% | -12.53% |
| BRKR | BRUKER CORP | 0.32% | $58.23 | +1.11% | +5.17% | -7.98% |
| FLGT | FULGENT GENETICS INC | 0.30% | $20.22 | +0.60% | +0.60% | -9.57% |
| MLAB | MESA LABORATORIES INC | 0.28% | $129.87 | +0.94% | +5.32% | -2.35% |
| DGX | QUEST DIAGNOSTICS INC | 0.26% | $242.95 | +0.44% | +3.42% | +2.24% |
| PRME | PRIME MEDICINE INC | 0.26% | $3.61 | -1.63% | -5.74% | +25.57% |
| RGNX | REGENXBIO INC | 0.23% | $6.58 | -1.50% | -7.97% | -11.91% |
| BNTC | BENITEC BIOPHARMA INC | 0.21% | $8.59 | -0.69% | +2.75% | -14.27% |
| EDIT | EDITAS MEDICINE INC | 0.18% | $2.4 | +0.00% | -0.83% | -4.38% |
| RCKT | ROCKET PHARMACEUTICALS INC | 0.18% | $2.28 | -0.44% | +1.79% | -12.64% |
| LAB | STANDARD BIOTOOLS INC | 0.14% | $0.6 | -0.92% | -6.73% | -17.50% |
| CRBU | CARIBOU BIOSCIENCES INC | 0.04% | $0.49 | -7.62% | +6.08% | -59.98% |